Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Iovance Biotherapeutics Inc
(NQ:
IOVA
)
11.87
+0.25 (+2.15%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Iovance Biotherapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics
April 05, 2024
These companies are in the early days of their growth stories.
Via
The Motley Fool
2 Soaring Growth Stocks That Could Climb Another 47% to 73%, According to Wall Street
March 26, 2024
Find out why investment banks up and down Wall Street have big expectations for these stocks.
Via
The Motley Fool
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
March 22, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
March 19, 2024
Via
Benzinga
Unpacking the Latest Options Trading Trends in Iovance Biotherapeutics
March 13, 2024
Via
Benzinga
(IOVA) - Analyzing Iovance Biotherapeutics's Short Interest
March 01, 2024
Via
Benzinga
Spotlight on Iovance Biotherapeutics: Analyzing the Surge in Options Activity
February 29, 2024
Via
Benzinga
Iovance Biotherapeutics: Q4 Earnings Insights
February 28, 2024
Via
Benzinga
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
March 18, 2024
With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas.
Via
InvestorPlace
Forget Eli Lilly. Buy This Magnificent Biotech Stock Instead
March 18, 2024
This company's growth story is about to get moving with gusto.
Via
The Motley Fool
Piper Sandler Maintains Overweight Rating for Iovance Biotherapeutics: Here's What You Need To Know
March 14, 2024
Via
Benzinga
Truist Securities Maintains Buy Rating for Iovance Biotherapeutics: Here's What You Need To Know
March 07, 2024
Via
Benzinga
1 Wall Street Analyst Thinks Iovance Biotherapeutics Stock Is Going to $32. Is It a Buy Around $17?
March 07, 2024
Its revenue is set to grow, and one of its trials is no longer paused.
Via
The Motley Fool
Iovance Biotherapeutics Stock Has 22% Upside, According to 1 Wall Street Analyst
March 06, 2024
With its first approval in hand, attention is now on the top line.
Via
The Motley Fool
Iovance Biotherapeutics's Earnings: A Preview
February 27, 2024
Via
Benzinga
Is Iovance a Buy After Its First Regulatory Win?
February 25, 2024
Iovance Biotherapeutics has found a new way to treat cancer.
Via
The Motley Fool
Unpacking the Latest Options Trading Trends in Iovance Biotherapeutics
February 23, 2024
Via
Benzinga
Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer
March 04, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Could Iovance Biotherapeutics Stock Help You Become a Millionaire?
March 02, 2024
Does Iovance Biotherapeutics stock possess enough upside to generate life-changing returns for your portfolio?
Via
The Motley Fool
Iovance Biotherapeutics to Present at Upcoming Conferences
March 01, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Why Iovance Biotherapeutics Stock Got Trounced on Thursday
February 29, 2024
A robust rally ended abruptly with the publication of the company's latest fundamentals.
Via
The Motley Fool
Iovance Biotherapeutics Unusual Options Activity For February 22
February 22, 2024
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
February 29, 2024
Via
Benzinga
Iovance Therapeutics Stock Has Skyrocketed Over 100% so Far This Year. Is It Still a Buy?
February 29, 2024
More gains might be on the way for this high-flying biotech stock.
Via
The Motley Fool
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
February 28, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
3 Stocks Flashing Recent Insider Buying Signals
February 27, 2024
One way to spot an opportunity is by paying attention to insider buying stocks. After all, it’s the insiders that know their company.
Via
InvestorPlace
3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024
February 26, 2024
Find out which under-the-radar biotech stocks have major catalysts on the horizon, and unlock their explosive growth potential.
Via
InvestorPlace
1 Soaring Growth Stock That Could Rise Another 53%, According to Wall Street
February 26, 2024
A successful launch of its first approved therapy could push shares of this innovative new cancer drug developer through the roof.
Via
The Motley Fool
This Biotech Stock Has 47% Upside, According to 1 Wall Street Analyst
February 23, 2024
It has good news in hand and plenty of room to grow.
Via
The Motley Fool
2 Top Biotech Stocks That Wall Street Thinks Could Soon Double in Value
February 23, 2024
These two businesses have viable paths to making investors richer -- possibly soon.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.